Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on AI-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. The company's lead drug candidate, rencofilstat, is involved in reducing liver fibrosis and is currently in Phase 2 clinical development for the treatment of NASH.

Hepion Pharmaceuticals

Hepion Pharmaceuticals | 1,885 followers on LinkedIn. Hepion Pharmaceuticals, Inc. is not affiliated in any way with Wire™ or Wire Swiss GmbH in any capacity. | Hepion Pharmaceuticals (Nasdaq: HEPA) is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies.

Regulatory Affairs | Clinical Development

Jill Greytok

CEO and founder / Roberts Communications

Susan Roberts

Professional and Driven Leader

Michael Fochesato

Director, Quality Assurance | cGCP| cGMP

Zenayda Pica

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals, Inc. Common Stock

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 9, 2024 10:01 PM	b945a980
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 9, 2024 10:01 PM	e069ab89
crunchbase trigger	general	Nov 9, 2024 10:01 PM	738e789f
crunchbase profile	general
li profile	general	Nov 9, 2024 10:01 PM	984ada6b
translate crunchbase fundingrounds	general
peers	general	Nov 9, 2024 10:01 PM	d583de29
news basic	general	Nov 9, 2024 10:01 PM	f27e63bd
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:HEPIONPHARMA

Hepion Pharmaceuticals

Last Close

0.69

22/11 21:00

Market Cap

4.62M

Beta: -

Volume Today

19.61K

Avg: -